Flortanidazole F 18

Drug Profile

Flortanidazole F 18

Alternative Names: 18F-flortanidazole; [18F]-HX4; Flortinidazole (18F)

Latest Information Update: 29 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Siemens AG
  • Developer Maastricht University; Siemens AG; Threshold Pharmaceuticals
  • Class Nitroimidazoles; Radiopharmaceutical diagnostics; Small molecules; Triazoles
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Head and neck cancer; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 29 Jun 2017 Flortanidazole F 18 is available for licensing as of 29 Jun 2017. http://www.thresholdpharm.com/overview-1/
  • 27 Mar 2017 Discontinued - Phase-I for Solid tumours (Diagnosis) in Netherlands (Parenteral)
  • 27 Mar 2017 Discontinued - Phase-II for Head and neck cancer (Diagnosis, Metastatic disease, Recurrent) in Australia and USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top